Bergur V. Stefánsson

Gentofte Hospital — Denmark

Medicine · Health Sciences

33h-index9.4kcitations83works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(58), Chronic Kidney Disease and Diabetes(25), Pancreatic function and diabetes(24), Diabetes Management and Research(16), Metabolism, Diabetes, and Cancer(15)

Publications80 total

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
Nephrology Dialysis Transplantation·2022· 29 citedOpen Access
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD
Journal of the American Society of Nephrology·2022· 74 citedOpen Access
866-P: Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis from the DAPA-CKD Study
Diabetes·2022
FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose
Nephrology Dialysis Transplantation·2022
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
Diabetologia·2022· 64 citedOpen Access
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
Kidney International Reports·2022· 15 citedOpen Access
POS-202 DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE TREATED WITH MINERALOCORTICOID RECEPTOR ANTAGONISTS: PRE-SPECIFIED ANALYSIS OF THE DAPA-CKD TRIAL
Kidney International Reports·2022Open Access
POS-255 EFFECT OF DAPAGLIFLOZIN ON BLOOD PRESSURE IN PATIENTS WITH CKD: A PRE-SPECIFIED ANALYSIS FROM DAPA-CKD
Kidney International Reports·2022· 7 citedOpen Access
Quételet (body mass) index and effects of dapagliflozin in chronic kidney disease
Diabetes Obesity and Metabolism·2022· 16 citedOpen Access
Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study
BMJ Open·2022· 16 citedOpen Access
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
UCL Discovery (University College London)·2022· 40 cited
Author response for "Quételet (Body Mass) Index and Effects of Dapagliflozin in CKD"
2021
Author response for "Quételet (Body Mass) Index and Effects of Dapagliflozin in CKD"
2021Open Access
The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
Kidney International Reports·2021· 88 citedOpen Access
Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials
Advances in Therapy·2021· 41 citedOpen Access
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
Nephrology Dialysis Transplantation·2021· 89 citedOpen Access
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
The Lancet Diabetes & Endocrinology·2021· 187 citedOpen Access
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
The Lancet Diabetes & Endocrinology·2021· 181 citedOpen Access
Quételet (Body Mass) Index and Effects of Dapagliflozin in CKD
Journal of the American Society of Nephrology·2021· 1 cited
The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure
European Heart Journal·2021
page 1 of 4Next →

Frequent Co-authors

Hiddo J.L. Heerspink(34), David C. Wheeler(32), Peter Rossing(29), Glenn M. Chertow(28), John J.V. McMurray(27), C. David Sjöström(27), Ricardo Correa‐Rotter(25), Anna Maria Langkilde(25), Robert D. Toto(24), Fan Fan Hou(19), Niels Jongs(18), Tom Greene(14), Priya Vart(10), David Z.I. Cherney(7), Valerie A. Cain(7), Johannes F.E. Mann(5), David P. Rosenbaum(5), Harpreet S. Bajaj(5), Peter J. Greasley(5), Börje Haraldsson(5)